2-methoxyestradiol has been researched along with pyrazines in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, KC; Auclair, D; Chauhan, D; Chen, LB; Hideshima, T; Li, G; Mitsiades, C; Mitsiades, N; Munshi, N; Podar, K; Saxena, S | 1 |
| Fu, W; Hou, J; Jiang, H; Wang, D; Yuan, Z; Zhou, L | 1 |
| Huang, HB; Lin, J; Wu, SQ; Xu, ZZ; Zhan, R | 1 |
| Gu, JL; Huang, BH; Li, J; Liu, JR; Su, C; Zheng, D; Zhou, ZH | 1 |
| Gartel, AL; Halasi, M; Hay, N; Nogueira, V; Pandit, B; Wang, M | 1 |
| Han, J; Heo, HJ; Jeong, SH; Jeong, YJ; Kim, HK; Kim, N; Ko, KS; Ko, TH; Lee, SR; Rhee, BD; Song, IS; Youm, JB | 1 |
6 other study(ies) available for 2-methoxyestradiol and pyrazines
| Article | Year |
|---|---|
2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27.
Topics: 2-Methoxyestradiol; Actins; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Estradiol; Heat-Shock Proteins; Humans; Multiple Myeloma; Peptides; Proteasome Inhibitors; Pyrazines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2004 |
Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib.
Topics: 2-Methoxyestradiol; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; beta Catenin; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Estradiol; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Oxides; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured | 2008 |
[Mechanism associated to enhancing the sensitivity of myeloma cells U266 to bortezomib by 2-methoxyestradiol].
Topics: 2-Methoxyestradiol; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Estradiol; Humans; Pyrazines | 2011 |
Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma.
Topics: 2-Methoxyestradiol; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Estradiol; Humans; Multiple Myeloma; Pyrazines; Regulatory Factor X Transcription Factors; Transcription Factors; Tretinoin; Tumor Cells, Cultured; X-Box Binding Protein 1 | 2012 |
Combination of oxidative stress and FOXM1 inhibitors induces apoptosis in cancer cells and inhibits xenograft tumor growth.
Topics: 2-Methoxyestradiol; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Administration Schedule; Estradiol; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Humans; Isothiocyanates; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Oxidative Stress; Pyrazines; Random Allocation; Reactive Oxygen Species; RNA Interference; Transplantation, Heterologous; Treatment Outcome | 2013 |
Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells.
Topics: 2-Methoxyestradiol; Acetylcysteine; Apoptosis; Boronic Acids; Bortezomib; Calcium; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Humans; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Pyrazines; Reactive Oxygen Species | 2013 |